The naïveté of some people is truly astounding. Fougera is making its numbers, Pharmaderm is not. THAT is a fact. Pharmaderm IS outsourcing sales rep positions. THAT is a fact. Solaraze IS going generic. THAT is a fact. There isn't enough of a remaining branded portfolio to support the number of sales reps we have so a down-size IS coming. The timing is likely to be 4Q when the powers that be will be looking for more ways to slow/stop the bleeding before year end.
This isn't a doomsday prophecy, it's an anticipated result based on an analysis of facts.
